LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities.
Brindle and Bay Financial Advisors LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) during the fourth quarter, according to the company in its most recent disclosure with the Securiti
AEGON ASSET MANAGEMENT UK Plc trimmed its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 8.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Comm
Calamos Advisors LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 3.9% during the fourth quarter, according to the company in its most recent filing with the Securities and
Gilead Sciences (GILD) reached $130.4 at the closing of the latest trading day, reflecting a -2.42% change compared to its last close.
Atwood and Palmer Inc. lifted its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 1.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the Secu
IBM warns of potential consumer slowdown, Microsoft targets AI push in Australia, and more
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2026 financial results and guidance will be released on Thursday, May 7, 2
BMY stands out vs GILD, supported by a cheaper valuation, strong growth portfolio, and improving earnings outlook despite generic headwinds.
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $135.87, denoting a -1.29% move from the preceding trading day.
Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $14
Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the business's stock in a transaction dated Wednesday, April 15th. The shares were sold at an average p
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE